FOREIGN FIRMS WILL HAVE DIRECT RESPONSIBILITY FOR MDR WITH IMPLEMENTATION OF RULE ON JULY 31; STAY WILL ELIMINATE U.S. AGENT, CEO CERTIFICATION LANGUAGE
This article was originally published in The Gray Sheet
Executive SummaryForeign device manufacturers who sell products in the U.S. will be required to report adverse events directly to FDA as of July 31, when FDA's medical device reporting rule goes into effect, agency staffers say.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.